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Abstract
Population-based genome wide association studies have identified a locus at 9p22.2 asso-
ciated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and
BRCA2mutation carriers. We conducted fine-scale mapping at 9p22.2 to identify potential
causal variants in BRCA1 and BRCA2mutation carriers. Genotype data were available for
15,252 (2,462 ovarian cancer cases) BRCA1 and 8,211 (631 ovarian cancer cases) BRCA2
mutation carriers. Following genotype imputation, ovarian cancer associations were
assessed for 4,873 and 5,020 SNPs in BRCA1 and BRCA 2 mutation carriers respectively,
within a retrospective cohort analytical framework. In BRCA1mutation carriers one set of
eight correlated candidate causal variants for ovarian cancer risk modification was identified
(top SNP rs10124837, HR: 0.73, 95%CI: 0.68 to 0.79, p-value 2× 10−16). These variants
were located up to 20 kb upstream of BNC2. In BRCA2mutation carriers one region, up to
45 kb upstream of BNC2, and containing 100 correlated SNPs was identified as candidate
causal (top SNP rs62543585, HR: 0.69, 95%CI: 0.59 to 0.80, p-value 1.0 × 10−6). The can-
didate causal in BRCA1mutation carriers did not include the strongest associated variant at
this locus in the general population. In sum, we identified a set of candidate causal variants
in a region that encompasses the BNC2 transcription start site. The ovarian cancer associa-
tion at 9p22.2 may be mediated by different variants in BRCA1mutation carriers and in the
general population. Thus, potentially different mechanisms may underlie ovarian cancer
risk for mutation carriers and the general population.
Introduction
Once age is taken into account, family history is the strongest risk factor for ovarian cancer.
Women with a first-degree relative with ovarian cancer are at a 3-fold increased risk of
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developing the disease, indicating the importance of genetic factors in ovarian cancer predispo-
sition. The most important genes in the context of genetic counseling for ovarian cancer sus-
ceptibility are BRCA1 and BRCA2, which account for approximately 24% of the familial risk
among first-degree relatives [1]. In contrast to the general population, in which the lifetime
risk of developing ovarian carcinoma is 1.6% (average age at diagnosis 63 years), women carry-
ing a BRCA1mutation have a lifetime risk of 35–60% with an average age of diagnosis of 50
years [2]. The ovarian cancer penetrance is lower for BRCA2, with a lifetime risk of 12–25%
and an average age of diagnosis of 60 years [2]. The majority of BRCA1/2 associated ovarian
cancers present as high-grade serous histology in advanced stage [3].
Genome wide association studies have identified several common germline variants associ-
ated with ovarian cancer risk. The 9p22 locus was first found to be associated with ovarian can-
cer risk in the general population, and subsequently to be an ovarian cancer risk modifier in
BRCA1 and BRCA2mutation carriers [4,5]. The SNP showing the strongest association in the
general population was rs3814113, which was associated with a decrease in the risk of ovarian
cancer in carriers of the minor allele (OR per allele = 0.82, 95%CI: 0.79 to 0.86, p-
value = 5.1 × 10−19) [5] and had a similar association with ovarian cancer risk for BRCA1 and
BRCA2mutation carriers [4]. rs3814113 lies in a 150-kb linkage disequilibrium (LD) block.
The closest genes to rs3814113 are Basonuclin 2(BNC2) and Centlein (CNTLN). BNC2 is a
zinc-finger protein spanning nucleotides 16409503 to 16870706. It is expressed in ovary, testis
and the male germ line where it regulates cell cycle progression [6]. CNTLN spans nucleotides
17134982 to 17503923, it is ubiquitously expressed and localises at centrosomes to ensure cen-
trosome function during cell division [7,8]. However, no fine-scale mapping of this locus has
been reported yet in either the general population or in mutation carriers. Therefore, it is
unclear which are the likely causal variants in the region.
Here, we report the fine-scale mapping of the 9p22.2 locus using data from 15252 BRCA1
and 8211 BRCA2mutation carriers of European ancestry. We comprehensively characterized
the associations of genetic variants in the region with ovarian cancer risk for BRCA1 and
BRCA2mutation carriers.
Materials and Methods
Study Population
Epidemiological and genotype data were obtained from BRCA1 and BRCA2mutation carriers
participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA, [9]). Eligi-
bility to CIMBA was restricted to women older than age 18 years who carried pathogenic muta-
tions in the BRCA1 or BRCA2 genes. For each mutation carrier, date of birth, age at cancer
diagnosis, age at bilateral prophylactic mastectomy and/or oophorectomy, age at interview or
last follow-up, exact BRCA1 and BRCA2mutation description and self-reported ethnicity were
recorded, together with tumor pathology, survival, treatment and other established lifestyle/
hormonal risk factors for breast or ovarian cancer. Participants were recruited from 25 coun-
tries under ethically approved protocols and provided written informed consent.
Genotyping and Imputation
Genotyping was performed using the iCOGS Illumina array [10]. The quality control (QC) of
the genotyping data has been described in detail previously [11,12]. The iCOGS array included
SNPs for fine mapping of the 9p22.2 region. The fine mapping region was defined as Chromo-
some 9 positions: 16407967 to 17407967 (NCBI build 37). To select the SNPs for inclusion on
iCOGS, we considered all variants with minor allele frequencies of>0.02 from the 1000
Genomes Project (March 2010 version) and selected SNPs that were correlated at r2>0.1 with
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the SNP that had been identified through the GWAS (rs3814113), and the set of SNPs that
tagged all remaining SNPs in the region with r2>0.9. A total of 407 and 401 SNPs that were
included on iCOGS in the 9p22.2 region passed QC and were available for the analyses for
BRCA1 and BRCA2mutation carriers, respectively. Imputation of genotypes was based on the
phase 3 release of the 1000 Genome Project spanning nucleotides 16407967 to 17407967 (build
37) at chromosome 9 with a buffer region of 500bp, using IMPUTE2 v2 [13]. SNPs with an
“info”metric lower than 0.3 were considered poorly imputed and excluded from downstream
analyses. In addition, SNPs with a minor allele frequency (MAF) lower than 0.005 were
excluded from the association analyses.
Statistical Analysis and Computational Methods
The primary analysis evaluated the association between each variant and ovarian cancer risk.
To account for the non-random sampling of mutation carriers with respect to disease status,
the analysis was conducted within a retrospective cohort framework by modeling the likelihood
of the observed genotypes conditional on the disease phenotypes as previously described [14].
Each mutation carrier was followed until the first of: ovarian cancer diagnosis, risk-reducing
salpingo-oophorectomy or age at last observation. Only those diagnosed with ovarian cancer
were considered as cases. The effect of each SNP was modeled as a per-allele Hazard Ratio
(HR). To account for related individuals in the sample, a kinship-adjusted version of the score
test for association was used which accounts for the correlation between the genotypes of the
relatives [15]. Analyses were carried out separately for BRCA1 and BRCA2mutation carriers
and all analyses were stratified by country of residence and year of birth. The USA and Canada
strata were further subdivided by reported Ashkenazi Jewish ancestry.
Ovarian cancer associations were combined in a meta-analysis between BRCA1 and BRCA2
mutation carriers. A fixed effect meta-analysis weighted by the inverse variance was conducted
for imputed and genotyped SNPs when risk estimates were available in both datasets. For
BRCA1 and BRCA2mutation carriers, logarithms of per-allele HR estimates were used. The
Cochran Q test was carried out to assess heterogeneity.
To assess the number of variants independently associated with ovarian cancer risk in
BRCA1 and BRCA2mutation carriers, each SNP was included in a Cox-regression model con-
ditioned on the most strongly associated variant for each dataset and further adjusting by year
of birth, and stratifying by country of residence. This approach has been shown to yield valid
tests of association [16]. All SNPs with a MAF>0.005, and imputation accuracy higher than
0.3, were included. For single SNP associations, associations were considered significant if
p<5x10-8. The most parsimonious model in the conditional analyses was identified using a
threshold of p<10−4 for retaining SNPs in the model.
The set of potential causal SNPs was defined by those SNPs for which their likelihood ratio
relative to the most significant variant was equal or less than 100 and having a pair-wise corre-
lation (r2) with the top SNP higher than 0.1 [17].
BEDTools was used to intersect positions of ovarian cancer risk-associated variants with
functional genomic features generated by Coetzee et al [18] including FAIRE-seq identified
regulatory elements and enhancers identified by histone modification ChIP-seq. Variants
implicated by overlap were then queried with HaploReg v3 (http://www.broadinstitute.org/
mammals/haploreg/haploreg_v3.php).
Ethics statement
Each of the host institutions recruited under ethically approved protocols. A list of the local
Institutional Review Boards that provided ethical approval for this study is given in S1 Table.
Fine-Scale Mapping at 9p22.2 in BRCA1 and BRCA2Mutations Carriers
PLOS ONE | DOI:10.1371/journal.pone.0158801 July 27, 2016 6 / 19
Results
Association of the 9p22.2 Locus with Ovarian Cancer Risk in BRCA1
Mutation Carriers
Data were available for 15,252 BRCA1mutation carriers of whom 2,462 were censored at
ovarian cancer diagnosis (S2 Table). After quality control, data for 407 SNPs genotyped
through the iCOGS array spanning chromosome 9 from positions 16424985 to 174 04464
(Genome built 37) were available. A further 36,769 SNPs were imputed using the 1000
Genome Project as reference panel. Of those, 4,873 had a MAF higher than 0.005 and were
considered reliably imputed (IMPUTE2 "info" score > 0.3), and were included in the associa-
tion analysis.
The strongest associated variant was the imputed SNP rs10124837 (per allele
HR = 0.73; 95%CI = 0.68–0.79; p = 2.0×10−16, Fig 1A, Table 1 and S1 Table) located
12 kb upstream of BNC2. SNP rs3814113 that was originally identified through the
GWAS demonstrated a weaker association (p = 5.2x10-13). The correlation between
the top SNP and the rs3814113 was 0.56 (Table 2). In total, 292 SNPs showed evidence
of association with ovarian cancer risk (p: 10−4 to 10−16, Fig 1A). The correlation between
the top SNP and the SNPs in this set varied from 0.1 to 0.9 (Fig 1). Results for all SNPs are
presented in S3 Table.
Association of the 9p22.2 Locus with Ovarian Cancer Risk in BRCA2
Mutation Carriers
A total of 8,211 BRCA2mutation carriers were included in the analysis, of whom 631 were cen-
sored at ovarian cancer diagnosis (S2 Table). The association analysis included 5,020 SNPs
(401 genotyped) with MAF>0.005 that were reliably imputed (IMPUTE2 "info" score greater
than 0.3). The strongest associated SNP with ovarian cancer risk was rs62543585, with a MAF
of 0.20 and a per-allele HR = 0.69 (95%CI = 0.59–0.80; p = 1.0 × 10−6, Table 1). SNP
rs3814113 demonstrated a slightly weaker association (p = 6.7x10-6 Table 1, r2 with SNP
rs62543583 = 0.48, Table 2). Although for BRCA2 mutation carriers the p-values did not reach
GWAS statistical significance (5x10-8), given the strong prior evidence of association between
SNPs in the region and risk for BRCA1 carriers and in the general population we selected the
most significant SNPs as associated with ovarian cancer risk. Results for all SNPs with p<0.01
are presented in S3 Table.
Meta-analysis of BRCA1 and BRCA2Mutation Carriers
Since the majority of both BRCA1 and BRCA2 ovarian cancer associated cancer tumors are
high-grade serous ([19] and S2 Table) to increase the power of the association analyses, a
meta-analysis combining HRs for the association of variants with ovarian cancer risk in
BRCA1 and BRCA2 was conducted. Variants available in only one of the datasets were
excluded from the analysis (40 removed from BRCA1 and 187 from BRCA2). In the meta-anal-
ysis, the strongest associated variant was the genotyped SNP rs7046326 with a MAF of 0.25
and 0.24 in BRCA1 and BRCA2mutation carriers, respectively. It displayed an HR = 0.74 (95%
CI = 0.69–0.79; p = 6.2 × 10−21, Table 1 and Fig 2). The correlation with the top SNP in
BRCA1mutation carriers was 0.88 and with the top SNP in BRCA2mutation carriers 0.69
(Table 2). In addition, 148 SNPs reached genome wide significance (p< 5 × 10−8) for the asso-
ciation with ovarian cancer risk, including the original GWAS hit rs3814113 (Fig 2). No evi-
dence for heterogeneity in the associations for BRCA1 and BRCA2mutation carriers was
observed (Q-test, p-values>0.5, data not shown).
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Identifying Independent Signals for the Association of 9p22 and Ovarian
Cancer in BRCA1 and BRCA2Mutation Carriers
In BRCA1mutation carriers, no variant displayed evidence of an association at a p<10−4 after
analyses conditioning on rs10124837 (S1A Fig). The association with rs3814113, the original
Fig 1. Associations between SNPs in 9p22.2 with ovarian cancer risk for BRCA1 and BRCA2mutation
carriers. In each plot, the purple diamond corresponds to the strongest associated SNP and the colour code
indicates the linkage disequilibrium with respect to this variant. Horizontal lines indicate the -log10 p-value
such that the SNPs above the line are the potential causal ones. This set was defined based on a likelihood
ratio for a particular SNP as being less or equal than 100, relative to the most likely variant and r2>0.1. (A)
BRCA1mutation carriers, (B) BRCA2mutation carriers.
doi:10.1371/journal.pone.0158801.g001
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GWAS hit, became non-significant (p = 0.2) when rs10124837 was included as covariate in the
model (S1A Fig and Table 3). Similarly, in BRCA2mutation carriers no evidence of an associa-
tion was observed for any variant after conditioning on rs62543585 (p>10−4 S1B Fig). Neither
rs3814113 nor rs10124837 were significant at p<0.05 when rs62543585 was included as covari-
ate in the model while the latter still displayed an association with p = 5x10-3 (S1B Fig and
Table 3).
Taken together, these results indicate that in both BRCA1 and BRCA2mutation carriers
there is only one peak of association with ovarian cancer risk at 9p22.
Association of 9p22 and Ovarian Cancer in BRCA1 and BRCA2Mutation Carriers.
SNPs with a likelihood ratio relative to the most significant variant greater than 100 and having
an r2< 0.1 with the index SNP were excluded from being potentially causative. In BRCA1
mutation carriers, this identified eight highly correlated SNPs (r2>0.8), referred hereafter as
the "BRCA1 peak". These variants clustered in a 20kb region around the transcription start site
of BNC2 (positions: 16,847,520–16,891,647). The SNPs in this set displayed MAFs of 0.24–0.28
and imputation accuracy higher than 0.95 and two out of the eight were genotyped (Fig 1A and
Table 1 and S4 Table).
In BRCA2mutation carriers, 100 variants could not be rejected from being potentially
causal. The MAFs for these SNPs varied from 0.15 to 0.34 and had pairwise correlations with
the index SNP of greater than 0.4 (Fig 1B, S4 Table). The quality of imputation was>0.95 for
all except two variants (info = 0.68 and 0.46, S4 Table).
All except one (imputed SNP rs139555631) of the likely causal variants in BRCA1mutation
carriers were included in the set marking the potentially causal variants defined in BRCA2
mutation carriers. However, none of them were ranked within the top 60 associated variants in
BRCA2 carriers. The index SNP (rs10124837 in BRCA1mutation carriers was in linkage dis-
equilibrium with the index SNP (rs62543583) in BRCA2mutation carriers r2 = 0.76, Fig 1,
Table 2).
The original GWAS hit, rs3814113, was within the set of the strongest associated SNPs in
BRCA2mutation carriers, but was rejected from being potentially causal in BRCA1mutation
carriers.
In the BRCA1/2 meta-analysis, eleven SNPs were the set of potentially causal variants,
which included the eight identified in BRCA1 plus three only present in the BRCA2 set. These
eleven variants were highly correlated with the lead SNP of the meta-analysis rs7046326
(r2>0.8). Of note, the set excluded the original GWAS hit rs3814113 (Fig 2, S5 Table).
Intersection of variants exhibiting the strongest associations with genomic features derived
from cultured ovarian and fallopian tube cells revealed several SNPs that may be functionally
relevant in influencing risk. Fig 3 shows the location of the sets of SNPs associated with ovarian
cancer risk in BRCA1 and BRCA2mutation carriers relative to the BNC2 gene. Several po-
tentially functional variants are predicted, including SNPs that lie in regulatory regions identi-
fied by FAIRE- and ChIP-seq. For example, a cluster of eight SNPs from the BRCA2 set of
Table 2. Pairwise correlations (r2) between selected SNPs. SNPs correspond to: rs10124837, the stron-
gest associated in BRCA1; rs62543583, the strongest associated in BRCA2mutation carriers; rs7046326,
the strongest associated in BRCA1/2meta-analysis; rs3814113, was the strongest associated variant in the
initial GWAS analysis.
SNP rs10124837 rs62543583 rs7046326 rs3814113
rs10124837 1 0.76 0.88 0.56
rs62543583 0.76 1 0.69 0.48
rs7046326 0.88 0.69 1 0.49
rs3814113 0.56 0.48 0.49 1
doi:10.1371/journal.pone.0158801.t002
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candidate causal variants lies within a ~10 kb region likely to carry regulatory activity encom-
passing the BNC2 transcription start site. Multiple transcription factor motifs are altered by
these variants (S6 Table). Although, no special features were observed for the variants in
Fig 2. Associations between SNPs in 9p22.2 with ovarian cancer risk for the meta-analysis ofBRCA1 and BRCA2
mutation carriers. (A) The purple diamond corresponds to the strongest associated SNP and the colour code indicates the
linkage disequilibrium with respect to this variant. Horizontal lines indicate the -log10 p-value such that the SNPs above the line
are the potential causal ones. This set was defined based on a likelihood ratio for a particular SNP as being less or equal than
100, relative to the most likely variant and r2>0.1. (B) Haplotype block indicating relevant SNPs. From left to right the indicated
SNPs correspond to: the strongest associated in BRCA1/2meta-analysis, the strongest in BRCA1 and the strongest in BRCA2.
doi:10.1371/journal.pone.0158801.g002
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BRCA1 or BRCA1/2meta-analysis (Fig 3), four of the eight candidate causal SNPs in BRCA1muta-
tion carriers are expressed single nucleotide polymorphism (eSNP) for the BNC2 gene in whole
blood samples (Table 1, data extracted from GTex Portal http://www.gtexportal.org/home/).
Discussion
In this study, we performed fine-scale mapping of the 9p22.2 locus using dense genotype data
from the iCOGS array in BRCA1 and BRCA2mutation carriers of European ancestry. We iden-
tified a set of variants that provided stronger evidence of association than the original GWAS
hit.
In BRCA1mutation carriers, one independent set of eight highly correlated (r2>0.8) SNPs
could not be excluded as being potentially causal for the reported association with ovarian can-
cer, designated the "BRCA1 peak". The BRCA1 peak covers positions 16847520 to 16891647,
which lie within or up to 20 kb upstream BNC2. Of note, the original GWAS hit rs3814113 was
excluded from the candidate causal variants in this peak.
For BRCA2mutation carriers, 100 correlated variants (r2>0.4) could not be excluded as
potentially causal ("BRCA2 peak"). The BRCA2 peak spanned positions 16847520 to 16915021,
which are up to 44 kb upstream of BNC2 and more than 200kb upstream of CNTLN. The
increased number of variants in this case is most likely due to reduced statistical power, as the
number of BRCA2mutation carriers diagnosed with ovarian cancer was only one quarter of
the number of affected BRCA1 carriers. The candidate causal SNPs in the BRCA1 peak were
mostly contained within the BRCA2 peak but the strongest associated SNP in BRCA2 was
excluded from the BRCA1 peak. The current analysis was underpowered to investigate whether
the association in BRCA2mutation carriers is driven by a different set of genetic variants.
Under the model of one shared causal variant explaining the association in both BRCA1 and
BRCA2mutation carriers, the meta-analysis would be expected to increase power for refining
the set of potential causal variants. However, the combined analysis of BRCA1 and BRCA2
mutation carriers defined a set of eleven variants as potentially causal, which corresponded to
the eleven strongest associated variants in BRCA1. This set excluded rs3814113 that was
reported in the ovarian cancer GWAS [5]. The set of candidate causal variants included three
additional SNPs that were confidently discarded on the basis of being less than 100 times likely
to be causal relative to the strongest associated SNP in the analysis of BRCA1 carriers only.
Important differences emerged when we compared the patterns of association in the fine-
scale mapping of 9p22.2 between BRCA1mutation carriers and results for the most strongly
associated SNPs in samples from the general population.
Table 3. Conditional associations forBRCA1 and BRCA2 top SNPs. The table shows the HR estimate.
95% CI and p-value for the conditional analysis adjusting for the lead SNP in the univariate analysis
forBRCA1 (left hand side) or BRCA2mutation carriers (right had side). SNPs correspond to:
rs10124837, the strongest associated in BRCA1; rs62543583, the strongest associated in BRCA2mutation
carriers; rs7046326, the strongest associated in BRCA1/2meta-analysis; rs3814113, was the strongest
associated variant in the initial GWAS analysis. “HR”, hazard ratio; “CI”, confidence interval.
BRCA1 (adj. rs10124837) BRCA2 (adj. rs62543583)
SNP HR 95%CI p-value HR 95%CI p-value
rs62543583 1.0 (0.76, 1.24) 0.99 0.67 (0.51, 0.88) 4.0x10-3
rs10124837 0.8 (0.72, 0.88) 9.0x10-5 0.99 (0.78, 1.27) 0.96
rs62543583 0.75 (0.61, 0.92) 5.0x10-3
rs3814113 0.87 (0.74, 1.03) 0.11
rs10124837 0.8 (0.72, 0.88) 1.5x10-5
rs3814113 0.9 (0.86, 1.03) 0.20
doi:10.1371/journal.pone.0158801.t003
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Fine-mapping results based on iCOGS data from the Ovarian Cancer Association Consor-
tium indicate that SNP rs3814113 remains the most strongly associated SNP at the 9p22.2 region
with serous ovarian cancer, the original GWAS hit (personal communication). Based on our
results, this SNP can be confidently rejected from the set of possible causal variants in BRCA1
mutation carriers, suggesting that the associations in BRCA1mutation carriers and in the general
population may be driven by different causal variants at the 9p22.2 locus. These results may indi-
cate differences in the underlying causal mechanisms explaining the ovarian cancer associations
between BRCA1mutation carriers and the general population. In support of this possibility, dif-
ferences in the association patterns with ovarian cancer between BRCA1 and the general popula-
tion have been reported before. The 4q32.3 locus is associated with ovarian cancer risk in BRCA1
but not in BRCA2mutation carriers or the general population [11], while the opposite is true for
the locus 17q11.2 [21]. However, clearer patterns will hopefully emerge once the fine mapping of
the 9p22.2 region in samples from the general population is completed.
As both signals lie in close proximity to the BNC2 gene, and some candidate causal SNPs
are eSNPs for BNC2 in whole blood, they may modulate the expression of BNC2 through simi-
lar, or different, mechanisms. The possibility that the BRCA1 association signal may differ
from that in the general population adds extra complexity and reinforces the value of fine-scale
mapping in different populations. These subtle differences in the patterns of associations
depending on the underlying genetic landscape may be difficult to uncover by means other
Fig 3. Genomic features surrounding the 9p22.2 locus. Illustration of the genomic region (chr9:16,839,835–16,924,468) encompassing peaks
(shaded areas) containing candidate causal variants associated with ovarian cancer risk in BRCA1 and BRCA2mutation carriers. Epigenomic data from
Coetzee et al., (2015) [20] representing potential regulatory elements in ovarian cells (iOSE4 and iOSE11) and fallopian tube (FTSEC33) cells derived
from formaldehyde assisted identification of regulatory elements sequencing (FAIRE-seq) and histone modification ChIP-seq are shown as black bars.
Variants which overlap one of these features are coloured red. Data from the ENCODE project including histone modification ChIP-seq for three
modifications (H3K4me1, H3K4me3, and H3K27ac) are shown as coloured histograms, as well as DNaseI hypersensitive site mapping and
transcription factor ChIP-seq. The positions of all common SNPs from dbSNP build 142 are shown in the lowest track.
doi:10.1371/journal.pone.0158801.g003
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than fine-scale mapping, and thus strengthens the value of this approach for generating
hypotheses about the functional basis of different sets of variants.
This study cannot exclude the possibility that the actual causal variants were not included in
the set of genotyped or well-imputed variants. However, the iCOGs array included variants
specifically for fine-scale mapping of the 9p22.2 locus based on data from the 1000 Genomes
Project and therefore the region coverage is expected to be high. The relatively low number of
ovarian cancer cases with tumor morphology information did not allow performing stratified
analyses by ovarian cancer histological subtype. Studies of ovarian tumours in women with
BRCA1 or BRCA2 mutations have shown that BRCA1 and BRCA2 carriers predominantly
develop serous disease [19,22]. Of the available data in CIMBA, 67% of all ovarian cancer
tumours in our analyses were serous ovarian cancers. Our results are therefore more compara-
ble with the associations for serous ovarian cancer in the general population. Larger studies
will be required to assess whether the patterns of associations differ by ovarian cancer histologi-
cal subtyped in BRCA1and BRCA2mutation carriers.
Having narrowed down the potential set of causal variants to only eight SNPs in BRCA1
mutation carriers will assist functional studies to identify the gene/s targeted by these variants.
BNC2 is an obvious candidate gene, given that the putative causal variants are located in/
around its transcription start site. Identifying more strongly associated variants with ovarian
cancer in the 9p22.2 region relative to the initial GWAS hit in BRCA1 and BRCA2mutation
carriers will refine the cancer risks associated with this locus further. These novel variants can
be included in polygenic risk scores for ovarian cancer and hence inform the identification of
patients at greater risk of disease. The results may also help to deepen our understanding of the
biology of ovarian cancer development in BRCA1 and BRCA2mutation carriers, potentially
leading to the development of more effective and personalized treatments.
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